Location History:
- Les Ulis, NC (US) (2004)
- Les Ulis, FR (2004 - 2008)
Company Filing History:
Years Active: 2004-2008
Title: The Innovative Contributions of Michael Lawrence Sierra
Introduction
Michael Lawrence Sierra is a notable inventor based in Les Ulis, France. With an impressive portfolio of nine patents, he has made significant contributions to the field of pharmaceuticals, particularly in treatments related to PPAR (peroxisome proliferator-activated receptor) disorders. His work demonstrates a commitment to advancing medical science through innovative solutions.
Latest Patents
Among his latest patents are two noteworthy inventions. The first involves thiazole derivatives aimed at treating PPAR related disorders, providing combinations of compounds that offer therapeutic benefits for PPAR related diseases. The second patent focuses on phenyloxyalkanonic acid derivatives as human PPAR activators. This invention outlines a compound with a specific formula, which includes pharmaceutically acceptable salts and esters, signifying a potential new route for therapeutic intervention.
Career Highlights
Michael Lawrence Sierra has had a distinguished career which includes working with prominent companies such as SmithKline Beecham Corporation and Lilly Icos LLC. His experiences in these organizations have undoubtedly enriched his expertise and expanded his innovative capabilities in the pharmaceutical domain.
Collaborations
Throughout his career, Sierra has collaborated with esteemed colleagues, including Millard Hurst Lambert III and Esther Yu-Hsuan Chao. These partnerships have likely fostered a dynamic environment for idea exchange and innovation, contributing to his successful patent portfolio.
Conclusion
In conclusion, Michael Lawrence Sierra stands out as a significant figure in the world of inventions and innovations. His expertise in developing therapeutic compounds underscores the value of creativity and collaboration in addressing complex medical challenges. As he continues his work, the impact of his contributions will undoubtedly resonate within the field of pharmaceuticals for years to come.